Albireo is studying new approaches for modulating acids with new compounds to address adult liver disease. Adult cholestatic diseases are a diverse group of disorders known for the appearance of jaundice, fatigue, pruritus and/or complications of cirrhosis. The most common adult cholestatic liver diseases are primary biliary cholangitis and primary sclerosing cholangitis.
The Company has completed IND-enabling studies for a new preclinical candidate, A3907. A3907 is a selective apical sodium-dependent bile acid transporter (ASBT) inhibitor that has the potential to increase elimination of bile acids by both fecal and urinary excretion. In preclinical studies, A3907 showed a significant reduction in plasma levels of transaminases, total cholesterol and markers for cell damage, fibrosis, liver weight and liver total cholesterol levels.
Sodium taurocholate co-transporting polypeptide (NTCP) inhibitors work by blocking bile entry into the liver and have shown promise in treating viral liver disease, like Hepatitis B and D, and other cholestatic liver diseases. Albireo is currently developing an oral NTCP inhibitor, including A2342, which is expected to begin IND-enabling studies this year.